Sellas Life Sciences Group Inc
sellaslifesciences.comWhat Do They Do?
Develops cancer drug candidates, including a peptide immunotherapy and a small-molecule treatment, for people with blood cancers and solid tumors.
10-K for FY2025, filed Mar 19, 2026We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer…View ↗
Our lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that…View ↗
On March 31, 2022, we entered into an exclusive license agreement, or the GenFleet Agreement, with GenFleet Therapeutics (Shanghai), Inc.…View ↗
Who Are Their Customers?
3D Medicines is the licensee for GPS and GPS Plus in Greater China, with rights to develop and sell the candidates there.
10-K for FY2025, filed Mar 19, 2026In December 2020, the Company entered into the 3D Medicines Agreement pursuant to which the Company granted 3D Medicines a sublicensable…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$9.6MView ↗
- ▲ +46% (Loss)
- vs −$6.6M in Q2 FY2025
-
Jul 27, 2026
Arbitrator dismisses SELLAS's claims against 3D Medicines
The company was allocated approximately $1.0 million in legal fees; $13.0 million in disputed milestones are included in remaining potential milestones.
Sources
8-K, filed Jul 27, 2026
As previously disclosed, the Company commenced a binding arbitration against 3D Medicines, Inc. (“3D Medicines”), administered by the Hong…View ↗
Who Do They Compete With?
Competes with AbbVie, Genentech, Pfizer, Daiichi-Sankyo, Rigel Pharmaceuticals, Syndax Pharmaceuticals, Bristol Myers Squibb, Curis, Delta-Fly Pharma, AROG Pharmaceuticals, Sumitomo Dainippon Pharma, Cothera Bioscience, and Prelude Therapeutics
10-K for FY2025, filed Mar 19, 2026Companies developing novel products with similar indications to those we are pursuing and may pursue are expected to influence our ability…View ↗
Loading...
